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were $17.44, $9.21 and $13.96 ans the cost/(change in
BPRS) were $2.91, $4.13 and $2.41 for clozapine, ris-
peridone and olanzapine respectively indicating olanza-
pine as the most cost-effective. The difference between
the cost/(change in BPRS) for olanzapine and risperidone
was statistically significant (P  0.036, t  2.1234,
df  98) ($1.72[$3.54–$0.10]). CONCLUSION: Re-
sults of our evaluation indicate that olanzapine is the
most cost-effective antipsychotic in our population of se-
vere and persistently mentally ill patients with schizo-
phrenia and schizoaffective disorders. We recommend
that simple cost-effective evaluations be made in every in-
stitution before deciding on the formulary or the pre-
ferred status of any atypical antipsychotic as it depends
upon many variables.
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The Disability In Strategies for Care (DISC) study dem-
onstrated that stratified care (where more disabled pa-
tients commenced treatment with zolmitriptan 2.5mg) re-
sulted in superior clinical outcomes compared with
conventional stepped care (where patients commenced
the same treatment regardless of disability). However
there are no prospective studies of the cost-effectiveness
of stratified care. OBJECTIVE: To assess the cost-effec-
tiveness of stratified care in managing migraine. METH-
ODS: A decision-analytic model was built to represent
primary care treatment of migraineurs under stepped and
stratified care, according to the treatment regimens in the
DISC study. A health service perspective was adopted,
with a one year time horizon. Data inputs were (i) the
frequency and disability of migraine, derived from popu-
lation-based studies. (ii) disability level-specific treatment
response rates for OTC analgesics, aspirin/metoclopra-
mide and zolmitriptan were obtained from an interna-
tional Delphi study; (iii) unit costs of healthcare in the US
(drug costs, primary and secondary care consultation
costs) obtained from health service sources. RESULTS:
The model estimated the cost per successfully treated at-
tack as $80 for stepped care and $45 for stratified care.
The estimated one-year direct healthcare costs were $534
for stepped care and $546 for stratified care. Estimates of
treatment response rates were 40% and 71% for stepped
and stratified care respectively.The incremental cost-
effectiveness for stratified care was $2.12 per additional
successfully treated attack. The cost-effectiveness of strat-
ified care was robust when tested in a wide range of sen-
sitivity analyses. CONCLUSION: Stratified care is a highly
cost-effective method of managing migraine delivering
improved clinical outcomes at minimal additional cost.
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Managed care companies vary substantially in the health-
care management of their membership as well as the fi-
nancial and contractual arrangement with their provider
networks. Therefore, formulary decision-makers could
benefit from customization of pharmacoeconomic deci-
sion models with plan-specific information. OBJEC-
TIVE: The purpose of this analysis was to validate results
of a pharmacoeconomic model for major depression by
customizing clinical and financial datasets specific to five
managed care organizations (MCOs). METHODS: A
pharmacoeconomic model was developed using decision
tree analysis over a six-month time horizon to assess the
acute phase of major depression for inpatients and out-
patients. Success and failure rates for TCAs, SSRIs and
SNRIs were obtained from a recent meta-analysis. Health-
care resources were incorporated into the model to deter-
mine the inpatient and outpatient costs of patient out-
comes. To facilitate site-specific customization of the
model, a software tool was developed enabling revisions
to the base-case practice patterns, resource valuation and
epidemiologic data. The model calculated expected cost
per patient, expected cost per-member-per-month (PMPM),
total annual cost, and 5-year total cost. RESULTS: Over
the five plans, the expected annual cost per outpatient
was the lowest for venlafaxine at $1,364 to $3,177 and
the highest for SSRIs at $1,881 to $4,311. Similarly, the
expected annual cost per inpatient again was the lowest
at $6,477 to $16,305 for venlafaxine and the highest at
$6,963 to $18,171 for the TCAs. CONCLUSIONS: Al-
though results varied across the five customizations of
the model, venlafaxine XR was the lowest cost alterna-
tive for all plans, validating the pharmacoeconomic re-
sults of the original model.
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Acute muscular low back pain (LBP) accounts for over
$30 billion in US annual medical costs, and is a leading
cause of absenteeism. LBP represents 16% of workers’
compensation claims and 33% of worker’s compensation
costs. Successful LBP treatment can yield substantial sav-
ings for the healthcare system and employers. OBJEC-
TIVE: To develop a model to estimate changes in health-
care utilization, absenteeism, and cost resulting from LBP
